ep exclud amort intang asset acquisition-rel cost impair charg
headquart marlborough develop manufactur suppli premium diagnost product
medic imag system surgic product women around world fy compani gener
billion revenu adjust ebitda billion current oper five segment breast health
diagnost gyn surgic medic aesthet skelet health
februari announc fiscal first quarter result revenu increas million versu
million guidanc cash ep increas versu guidanc compani provid
overview quarter reaffirmed/upd guidanc
diagnost revenu decreas million million exclud blood busi divestitur
januari diagnost increas million continu see strength aptima women
health assay perinat sale four addit sell day creat tough comparison
headwind consum side busi new panther system offer platform consolid
respiratori viral load assay drive growth
breast revenu increas million growth driven strong intern sale new
product servic revenu biopsi system placement brevera affirm increas
medic aesthet segment creat march cynosur acquisit gener million
year-over-year declin new salesforc hire complet quarter drive momentum busi
gyn surgic declin million due weak novasur sale stagnant ablat market
busi experienc tough comparison due competit recal benefit myosur continu grow
nice skelet health declin million expect quarterli increas remaind
geograph intern revenu grew excl cynosure/blood screen us revenu grew
declin excl cynosure/blood screen margin continu take hit blood screen divestitur
annual high margin busi replac lower margin cynosur gross margin contract
oper margin contract
passag us tax reform legisl guid tax rate year vs prior
save reinvest market initi project acceler see strong
flow-through bottom-line
fy re-affirmed revenu growth billion rais ep growth
previous growth rais ep attribut lower tax rate lower
share count solid perform quarter repurchas million convert
debt lever ebitda expect revenu growth million
ep growth
million except per share
compani data gabelli compani estim
despit deceler mammographi convers believ grow revenu billion
billion fiscal look beyond expect grow diagnost market
placement sale remain robust complement global opportun manag confid recent blood
screen divestitur cynosur integr underway medium-term growth driver includ cynosur new
product launch intern expans accret acquisit forecast ebitda billion
translat earn per share valu ebitda calcul fiscal pmv
per share recommend investor buy share
million except per share
current market discount pmv
after-tax payment buy option holder privat market valu
compani data gabelli compani estim
sara wojda research analyst prepar report herebi certifi view express report accur reflect analyst person
view subject compani secur research analyst receiv direct indirect compens
express specif recommend view report
public data octob buy recommend
